Gender issues in multiple sclerosis

Expert Review of Neurotherapeutics

Volumn 3, Issue 5, 2003, Pages 649-660

  McCombe, Pamela A ^a  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Gender; Immunology; Multiple sclerosis; Therapy

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; ESTRIOL; ESTROGEN; GAMMA INTERFERON; GLATIRAMER; GROWTH FACTOR; HORMONE; INTERFERON BETA SERINE; NATALIZUMAB; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; SOMATOMEDIN C; TAU INTERFERON; TESTOSTERONE;

CLINICAL TRIAL; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DEMYELINATING DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; FEMALE; GENDER; GENETIC PREDISPOSITION; HORMONAL REGULATION; HUMAN; IMMUNE RESPONSE; MALE; MENSTRUAL CYCLE; MULTIPLE SCLEROSIS; PREGNANCY; PUERPERIUM; RELAPSE; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; TH1 CELL; TH2 CELL; TREATMENT PLANNING;

EID: 0041375240     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.3.5.649     Document Type: Review

References (157)

1. Keegan BM, Noseworthy JH. Multiple sclerosis. Ann. Rev. Med 53, 285-302 (2002). Good recent review of multiple sclerosis.
2. Miller DH, Hammond SR, McLeod JG, Purdie G, Skegg DC. Multiple sclerosis in Australia and New Zealand, are the determinants genetic or environmental? J. Neurol. Neurosurg. Psychiatry 53, 903-905 (1990).
3. Forbes RB, Wilson SV, Swingler RJ. The prevalence of multiple sclerosis in Tayside, Scotland, do latitudinal gradients really exist? J. Neurol. 246, 1033-1040 (1999).
4. Forbes RB, Swingler RJ. Estimating the prevalence of multiple sclerosis in the United Kingdom by using capture-recapture methodology. Am. J. Epidemiol. 149, 1016-1024 (1999).
5. Elian M, Dean G. Multiple sclerosis among the United Kingdom-born children of immigrants from the West Indies. J. Neurol. Neurosurg. Psychiatry 50, 327-332 (1987).
6. van der Mei I, Ponsonby AL, Blizzard L, Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 20, 168-174 (2001).
7. Compston A. Risk factors for multiple sclerosis, race or place? J. Neurol. Neurosurg. Psychiatry 53, 821-823 (1990).
8. Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis, a geographically based study I. Clinical course and disability. Brain 112, 133-146 (1989).
9. Poser CM, Brinar VV. Diagnostic criteria for multiple sclerosis. Clin. Neurol. Neurosurg. 103, 1-11 (2000).
10. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis, guidelines for research protocols. Ann. Neurol. 13, 227-231 (1983).
11. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis, guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 50, 121-127 (2001).
12. Dalton CM, Brex PA, Miszkiel KA et al. Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann. Neurol. 52, 47-53 (2002).
13. McLean BN, Luxton RW, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain 113, 1269-1289 (1990).
14. Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS, consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 206, 165-171 (2003).
15. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions, implications for the pathogenesis of demyelination. Ann. Neurol. 47, 707-717 (2000). Important paper about modern concepts of the pathology and classifiaction of multiple sclerosis.
16. Allen IV, McQuaid S, Mirakhur M, Nevin G. Pathological abnormalities in the normal-appearing white matter in multiple sclerosis. Neurol. Sci. 22, 141-144 (2001).
17. Bjartmar C, Kinkel RP, Kidd G, Rudick RA, Trapp BD. Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57, 1248-1252 (2001). Emphasizes the loss of axons that may be found in multiple sclerosis.
18. Rudick RA. Evolving concepts in the pathogenesis of multiple sclerosis and their therapeutic implications. J. Neuroophthalmol. 21, 279-283 (2001).
19. Bruck W, Lucchinetti C, Lassmann H. The pathology of primary progressive multiple sclerosis. Mult. Scler. 8, 93-97 (2002).
20. Vukusic S, Confavreux C. Primary and secondary progressive multiple sclerosis. J. Neurol. Sci. 206, 153-155 (2003).
21. Hemmer B, Archelos JJ, Hartung HP. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3, 291-301 (2002).
22. Schwartz M, Kipnis J. Multiple sclerosis as a by-product of the failure to sustain protective autoimmunity, a paradigm shift. Neuroscientist 8, 405-413 (2002).
23. Neuhaus O, Archelos JJ, Hartung HP. Immunomodulation in multiple sclerosis, from immunosuppression to neuroprotection. Trends Pharmacol. Sci. 24, 131-138 (2003).
24. Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci. 3, 705-714 (2002).
25. O'Connor KC, Bar-Or A, Hafler DA. The neuroimmunology of multiple sclerosis, possible roles of T and B-lymphocytes in immunopathogenesis. J. Clin. Immunol. 21, 81-92 (2001).
26. Martino G, Hartung HP. Immunopathogenesis of multiple sclerosis, the role of T-cells. Curr. Opin. Neurol. 12, 309-321 (1999).
27. Archelos JJ, Storch MK, Hartung HP. The role of B-cells and autoantibodies in multiple sclerosis. Ann. Neurol. 47, 694-706 (2000).
28. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin-2-responsive T-cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179, 973-984 (1994).
29. Greer JM, Csurhes PA, Cameron KD, McCombe PA, Good MF, Pender MP. Increased immunoreactivity to two overlapping peptides of myelin proteolipid protein in multiple sclerosis. Brain 120, 1447-1460 (1997).
30. Reindl M, Linington C, Brehm U et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases, a comparative study. Brain 122, 2047-2056 (1999).
31. Mata S, Lolli F, Soderstrom M, Pinto F, Link H. Multiple sclerosis is associated with enhanced B-cell responses to the ganglioside GD1a. Mult. Scler. 5, 379-388 (1999).
32. Pender MP, Csurhes PA, Wolfe NP et al. Increased circulating T-cell reactivity to GM3 and GQ1b gangliosides in primary progressive multiple sclerosis. J. Clin. Neurosci. 10, 63-66 (2003).
33. Waubant E, Goodkin D, Bostrom A et al. IFN-β lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 60, 52-57 (2003).
34. Turner B, Lin X, Calmon G, Roberts N, Blumhardt LD. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult. Scler. 9, 21-27 (2003).
35. Losseff NA, Miller DH. Measures of brain and spinal cord atrophy in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 64(Suppl. 1), S102-S105 (1998).
36. Losseff NA, Webb SL, O'Riordan JI et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119, 701-708 (1996).
37. Lachenecker P, Reiners K, Krauser M, Wolf A, Toyka KV. Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Mult. Scler. 7, 327-334 (2001).
38. Rovaris M, Rocca MA, Filippi M. Magnetic resonance-based techniques for the study and management of multiple sclerosis. Br. Med. Bull. 65, 133-144 (2003).
39. Gold R, Hartung HP, Toyka KV. Animal models for autoimmune demyelinating disorders of the nervous system. Mol. Med. Today 6, 88-91 (2000).
40. Pender MP, Stanley GP, Yoong G, Nguyen KB. The neuropathology of chronic relapsing experimental allergic encephalomyelitis induced in the Lewis rat by inoculation with whole spinal cord and treatment with cyclosporin A. Acta Neuropathol. Berl. 80, 172-183 (1990).
41. Hammond SR, de Wytt C, Maxwell et al. The epidemiology of multiple sclerosis in Queensland, Australia. J. Neurol. Sci. 80, 185-204 (1987).
42. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology 49, 1404-1413 (1997).
43. Hely MA, McManis PG, Doran TJ, Walsh JC, McLeod JG. Acute optic neuritis, a prospective study of risk-factors for multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 49, 1125-1130 (1986).
44. Sandberg-Wollheim M, Bynke H, Cronqvist S, Holtas S, Platz P, Ryder LP. A long-term prospective study of optic neuritis, evaluation of risk factors. Ann. Neurol. 27, 386-393 (1990).
45. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116, 117-134 (1993).
46. Wolfson C, Confavreux C. A Markov model of the natural history of multiple sclerosis. Neuroepidemiology 4, 227-239 (1985).
47. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis, a geographically based study 3. Multivariate analysis of predictive factors and models of outcome. Brain 114, 1045-1056 (1991).
48. Poser S, Raun NE, Poser W. Age at onset, initial symptomatology and the course of multiple sclerosis. Acta. Neurol. Scand. 66, 355-362 (1982).
49. Pozzilli C, Tomassini V, Marinelli F, Paolillo A, Gasperini C, Bastianello S. Gender gap in multiple sclerosis, magnetic resonance imaging evidence. Eur. J. Neurol. 10, 95-97 (2003).
50. Voskuhl RR, Pitchekian-Halabi H, MacKenzie-Graham A, McFarland HF, Raine CS. Gender differences in autoimmune demyelination in the mouse, implications for multiple sclerosis. Ann. Neurol. 39, 724-733 (1996).
51. Bebo BF Jr, Schuster JC, Vandenbark AA, Offner H. Gender differences in experimental autoimmune encephalomyelitis develop during the induction of the immune response to encephalitogenic peptides. J. Neurosci. Res. 52, 420-426 (1998).
52. Abramsky O. Pregnancy and multiple sclerosis. Ann. Neurol. 36(Suppl) S38-S41, (1994).
53. Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain 118, 253-261 (1995).
54. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N. Engl. J. Med. 339, 285-291 (1998). The most important study of the effects of pregnancy on multiple sclerosis.
55. van Walderveen MA, Tas MW, Barkhof F et al. Magnetic resonance evaluation of disease activity during pregnancy in multiple sclerosis. Neurology 44, 327-329 (1994).
56. Verdru P, Theys P, D'Hooghe MB, Carton H. Pregnancy and multiple sclerosis, the influence on long-term disability. Clin. Neurol. Neurosurg. 96, 38-41 (1994).
57. Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A. Oral contraceptives and the incidence of multiple sclerosis. Neurology 55, 848-854 (2000).
58. Mertin LA, Rumjanek VM. Pregnancy and the susceptibility of Lewis rats to experimental allergic encephalomyelitis. J. Neurol. Sci. 68, 15-24 (1985).
59. Harness J, McCombe PA. The effects of pregnancy on myelin basic protein-induced experimental autoimmune encephalomyelitis in Lewis rats, suppression of clinical disease, modulation of cytokine expression in the spinal cord inflammatory infiltrate and suppression of lymphocyte proliferation by pregnancy sera. Am. J. Reprod. Immunol. 46, 405-412 (2001).
60. Zorgdrager A, De Keyser J. Menstrually related worsening of symptoms in multiple sclerosis. J. Neurol. Sci. 149, 95-97 (1997).
61. Kelly MJ, Ronnekleiv OK, Ibrahim N, Lagrange AH, Wagner EJ. Estrogen modulation of K(+) channel activity in hypothalamic neurons involved in the control of the reproductive axis. Steroids 67, 447-456 (2002).
62. Herbison AE. Estrogen regulation of GABA transmission in rat preoptic area. Brain Res. Bull. 44, 321-326 (1997).
63. Zorgdrager A, De Keyser J. The premenstrual period and exacerbations in multiple sclerosis. Eur. Neurol. 48, 204-206 (2002).
64. Pozzilli C, Falaschi P, Mainero C et al. MRI in multiple sclerosis during the menstrual cycle, relationship with sex hormone patterns. Neurology 53, 622-624 (1999).
65. Bansil S, Lee HJ, Jindal S, Holtz CR, Cook SD. Correlation between sex hormones and magnetic resonance imaging lesions in multiple sclerosis. Acta. Neurol. Scand. 99, 91-94 (1999).
66. Smith RS, Studd JW. A pilots study of the effect upon multiple sclerosis of the menopause, hormone replacement therapy and the menstrual cycle. J. R. Soc. Med. 85, 612-613 (1992).
67. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 103, 281-300 (1980).
68. Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A. Oral contraceptives and the incidence of multiple sclerosis. Neurology 55, 848-854 (2000).
69. Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosis. Br. J. Obstet. Gynaecol. 105, 1296-1299 (1998).
70. Kurtzke JF, Page WF. Epidemiology of multiple sclerosis in US veterans, VII. Risk factors for MS. Neurology 48, 204-213 (1997).
71. Mosmann TR, Coffman RL. Th1 and Th2 cells, different patterns of lymphokine secretion leads to different functional properties. Ann. Rev. Immunol. 7, 145-173 (1989).
72. Mosmann TR, Sad S. The expanding universe of T-cell subsets, Th1, Th2 and more. Immunol. Today 17, 138-146 (1996).
73. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship, is successful pregnancy a TH2 phenomenon? Immunol. Today 14, 353-356 (1993).
74. Mock BA, Nacy CA. Hormonal modulation of sex differences in resistance to Leishmania major systemic infections. Infect. Immun. 56, 3316-3319 (1988).
75. Huygen K, Palfliet K. Strain variation in interferon gamma production of BCG-sensitized mice challenged with PPD II. Importance of one major autosomal locus and additional sexual influences. Cell Immunol. 85, 75-81 (1984).
76. Weinstein Y, Ran S, Segal S. Sex-associated differences in the regulation of immune responses controlled by the MHC of the mouse. J. Immunol. 132, 656-661 (1984).
77. Pelfrey CM, Cotleur AC, Lee JC, Rudick RA. Sex differences in cytokine responses to myelin peptides in multiple sclerosis. J. Neuroimmunol. 130, 211-223 (2002).
78. Nguyen LT, Ramanathan M, Weinstock-Guttman B, Baier M, Brownscheidle C, Jacobs LD. Sex differences in in vitro proinflammatory cytokine production from peripheral blood of multiple sclerosis patients. J. Neurol. Sci. 209, 93-99 (2003).
79. Allen JS, Damasio H, Grabowski TJ, Bruss J, Zhang W. Sexual dimorphism and asymmetries in the gray-white composition of the human cerebrum. Neuroimage 18, 880-894 (2003).
80. Allen JS, Damasio H, Grabowski TJ. Normal neuroanatomical variation in the human brain, an MRI-volumetric study. Am. J. Phys. Anthropol. 118, 341-358 (2002).
81. Szabo CA, Lancaster JL, Xiong J, Cook C, Fox P. MR imaging volumetry of subcortical structures and cerebellar hemispheres in normal persons. AJNR Am. J. Neuroradiol. 24, 644-647 (2003).
82. Szabo CA, Xiong J, Lancaster JL, Rainey L, Fox P. Amygdalar and hippocampal volumetry in control participants, differences regarding handedness. AJNR Am. J. Neuroradiol. 22, 1342-1345 (2001).
83. Zup SL, Carrier H, Waters EM et al. Overexpression of bcl-2 reduces sex differences in neurone number in the brain and spinal cord. J. Neurosci. 23, 2357-2362 (2003).
84. Goldstein JM, Seidman LJ, Horton NJ et al. Normal sexual dimorphism of the adult human brain assessed by in vivo magnetic resonance imaging. Cereb. Cortex 11, 490-497 (2001).
85. Carrer HF, Cambiasso MJ. Sexual differentiation of the brain, genes, estrogen and neurotrophic factors. Cell. Mol. Neurobiol. 22, 479-500 (2002).
86. Rabinowicz T, Petetot JM, Gartside PS, Sheyn D, Sheyn T, de CM. Structure of the cerebral cortex in men and women. J. Neuropathol. Exp. Neurol. 61, 46-57 (2002).
87. Hawk T, Zhang YQ, Rajakumar G, Day AL, Simpkins JW. Testosterone increases and estradiol decreases middle cerebral artery occlusion lesion size in male rats. Brain Res. 796, 296-298 (1998).
88. Gartner J, Dehmel T, Klusmann A, Roerig P. Functional characterization of the adrenoleukodystrophy protein (ALDP) and disease pathogenesis. Endocr. Res. 28, 741-748 (2002).
89. Ebers GC, Kukay K, Bulman DE et al. A full genome search in multiple sclerosis. Nat. Genet. 13, 472-476 (1996).
90. Chataway J, Feakes R, Coraddu F et al. The genetics of multiple sclerosis, principles, background and updated results of the United Kingdom systematic genome screen. Brain 121, 1869-1887 (1998).
91. Chataway J, Mander A, Robertson N et al. Multiple sclerosis in sibling pairs, an analysis of 250 families. J. Neurol. Neurosurg. Psychiatry 71, 757-761 (2001).
92. Sawcer S, Jones HB, Feakes R et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat. Genet. 13, 464-468 (1996).
93. Duquette P, Pleines J, Girard M, Charest L, Senecal-Quevillon M, Masse C. The increased susceptibility of women to multiple sclerosis. Can. J. Neurol. Sci. 19, 466-471 (1992).
94. Celius EG, Harbo HF, Egeland T, Vartdal F, Vandvik B, Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J. Neurol. Sci. 178, 132-135 (2000).
95. Goris A, Heggarty S, Marrosu MG, Graham C, Billiau A, Vandenbroeck K. Linkage disequilibrium analysis of chromosome 12q14-15 in multiple sclerosis, delineation of a 118-kb interval around interferon-γ (IFNG) that is involved in male versus female differential susceptibility. Genes Immun. 3, 470-476 (2002).
96. Warren SA, Warren KG. Influence of gender on susceptibility to multiple sclerosis and age of onset in concordant sibships. Int. J. Epidemiol. 25, 142-145 (1996).
97. Sadovnick AD, Bulman DE, Hashimoto L, D'Hooghe MB, Ebers GC. The influence of gender on the susceptibility to multiple sclerosis in sibships. Arch. Neurol. 48, 586-588 (1991).
98. Okuda Y, Okuda M, Bernard CC. Gender does not influence the susceptibility of C57BL/6 mice to develop chronic experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein. Immunol. Lett. 81, 25-29 (2002).
99. Elenkov IJ, Wilder RL, Bakalov VK et al. IL-12, TNF-α and hormonal changes during late pregnancy and early post-partum, implications for autoimmune disease activity during these times. J. Clin. Endocrinol. Metab. 86, 4933-4938 (2001).
100. Bebo BF Jr, Zelinka-Vincent E, Adamus G, Amundson D, Vandenbark AA, Offner H. Gonadal hormones influence the immune response to PLP 139-151 and the clinical course of relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 84, 122-130 (1998).
101. Dalal M, Kim S, Voskuhl RR. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T-helper 2 bias in the autoantigen-specific T-lymphocyte response. J. Immunol. 159, 3-6 (1997).
102. Bebo BF Jr, Adlard K, Schuster JC, Unsicker L, Vandenbark AA, Offner H. Gender differences in protection from EAE induced by oral tolerance with a peptide analogue of MBP-Ac1-11. J. Neurosci. Res. 55, 432-440 (1999).
103. Offner H, Zamora A, Drought H et al. A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE. J. Neuroimmunol. 130, 128-139 (2002).
104. McCombe PA, Nickson I, Tabi Z, Pender MP. Apoptosis of Vβ 8.2+ T-lymphocytes in the spinal cord during recovery from experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein. J. Neurol. Sci. 139, 1-6 (1996).
105. Pender MP, McCombe PA, Yoong G, Nguyen KB. Apoptosis of αβ T-lymphocytes in the nervous system in experimental autoimmune encephalomyelitis, its possible implications for recovery and acquired tolerance. J. Autoimmun. 1992 5, 401-410.
106. Dulos GJ, Bagchus WM. Androgens indirectly accelerate thymocyre apoptosis. Int. Immunopharmacol. 1, 321-328 (2001).
107. Vermeulen A. Ageing, hormones, body composition, metabolic effects. World J. Urol. 20, 23-27 (2002).
108. Voskuhl RR, Palaszynski K. Sex hormones in experimental autoimmune encephalomyelitis, implications for multiple sclerosis. Neuroscientist 7, 258-270 (2001). Good review of the role of sex hormones in multiple sclerosis.
109. Kim S, Liva SM, Dalal MA, Verity MA, Voskuhl RR. Estriol ameliorates autoimmune demyelinating disease, implications for multiple sclerosis. Neurology 52, 1230-1238 (1999).
110. Subramanian S, Matejuk A, Zamora A, Vandenbark AA, Offner H. Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in SJL Mice and inhibits the recruitment of inflammatory cells into the central nervous system. J. Immunol. 170, 1548-1555 (2003).
111. Liu HY, Buenafe AC, Matejuk A et al. Estrogen inhibition of EAE involves effects on dendritic cell function. J. Neurosci. Res. 70, 238-248 (2002).
112. Ito A, Buenafe AC, Matejuk A et al. Estrogen inhibits systemic T-cell expression of TNF-α and recruitment of TNF-α(+) T-cells and macrophages into the CNS of mice developing experimental encephalomyelitis. Clin. Immunol. 102, 275-282 (2002).
113. Matejuk A, Dwyer J, Zamora A, Vandenbark AA, Offner H. Evaluation of the effects of 17 β-estradiol (17 β-e2) on gene expression in experimental autoimmune encephalomyelitis using DNA microarray. Endocrinology 143, 313-319 (2002).
114. Matejuk A, Adlard K, Zamora A, Silverman M, Vandenbark AA, Offner H. 17 β-estradiol inhibits cytokine, chemokine and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis. J. Neurosci. Res. 65, 529-542 (2001).
115. Sicotte NL, Liva SM, Klutch R et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann. Neurol. 52, 421-428 (2002). Trial showing that estriol may be beneficial in multiple sclerosis.
116. Tornwall J, Carey AB, Fox RI, Fox HS. Estrogen in autoimmunity, expression of estrogen receptors in thymic and autoimmune T-cells. J. Gend Specif. Med. 2, 33-40 (1999).
117. McEwen B. Estrogen actions throughout the brain. Recent Prog. Horm. Res. 57, 357-384 (2002).
118. Arnason BG, Richman DP. Effect of oral contraceptives on experimental demyelinating disease. Arch. Neurol. 21, 103-108 (1969).
119. Hoffman GE, Le WW, Murphy AZ, Koski CL. Divergent effects of ovarian steroids on neuronal survival during experimental allergic encephalitis in Lewis rats. Exp. Neurol. 171, 272-284 (2001).
120. Morton H, Cavanagh AC, Athanasas-Platsis S, Quinn KA, Rolfe BE. Early pregnancy factor has immunosuppressive and growth factor properties. Reprod. Fertil. Dev. 4, 411-422 (1992).
121. Zhang B, Harness J, Somodevilla-Torres MJ et al. Early pregnancy factor suppresses experimental autoimmune encephalomyelitis induced in Lewis rats with myelin basic protein and in SJL/J mice with myelin proteolipid protein peptide 139-151. J. Neurol. Sci. 182, 5-15 (2000).
122. Zhang B, Walsh NM, Nguyen KB et al. Early pregnancy factor treatment suppresses the inflammatory response and adhesion molecule expression in the spinal cord of SJL/J mice with experimental autoimmune encephalomyelitis and the delayed type hypersensitivity reaction to trinitrochlorobenzene in normal BALB/c mice. J. Neuol. Sci. (2003) (In Press).
123. Martal JL, Chene NM, Huynh LP et al. IFN-tau, a novel subtype I IFN-1. Structural characteristics, nonubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Biochimie 80, 755-777 (1998).
124. Filippini G, Munari L, Incorvaia B et al. Interferons in relapsing remitting multiple sclerosis, a systematic review. Lancet 361, 545-552 (2003).
125. Soos JM, Stuve O, Youssef S et al. Cutting edge, oral Type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J. Immunol. 169, 2231-2235 (2002).
126. Mujtaba MG, Streit WJ, Johnson HM. IFN-tau suppresses both the autoreactive humoral and cellular immune responses and induces stable remission in mice with chronic experimental allergic encephalomyelitis. Cell Immunol. 186, 94-102 (1998).
127. Langer-Gould A, Garren H, Slansky A, Ruiz PJ, Steinman L. Late pregnancy suppresses relapses in experimental autoimmune encephalomyelitis, evidence for a suppressive pregnancy-related serum factor. J. Immunol. 169, 1084-1091 (2002).
128. Brenner T, Evron S, Soffer D, Abramsky O. Treatment of experimental allergic encephalomyelitis in rabbits with α-fetoprotein. Isr. J. Med. Sci. 21, 945-949 (1985).
129. Abramsky O, Brenner T, Mizrachi R, Soffer D. α-fetoprotein suppresses experimental allergic encephalomyelitis. J. Neuroimmunol. 2, 1-7 (1982).
130. Kikukawa A, Peterson BS, Deutsch HF. Attempts to suppress experimental allergic encephalomyelitis in rats with α-fetoprotein. Tumour Biol. 9, 84-94 (1988).
131. Caspary EA, Hughes D. Experimental allergic encephalomyelitis in the guinea-pig. Failure to suppress with crude human chorionic gonadotrophin. J. Neurol. Sci. 34, 53-62 (1977).
132. McCombe PA, Nickson I, Tabi Z, Pender MF. Corticosteroid treatment of experimental autoimmune encephalomyelitis in the Lewis rat results in loss of Vβ 8.2+ and myelin basic protein-reactive cells from the spinal cord, with increased total T-cell apoptosis but reduced apoptosis of Vβ 8.2+ cells. J. Neuroimmunol. 70, 93-101 (1996).
133. Potau N, Ibanez L, Sentis M, Carrascosa A. Sexual dimorphism in the maturation of the pituitary-gonadal axis, assessed by GnRH agonist challenge. Eur. J. Endocrinol. 141, 27-34 (1999).
134. Liu X, Yao DL, Webster H. Insulin-like growth Factor I treatment reduces clinical deficits and lesion severity in acute demyelinating experimental autoimmune encephalomyelitis. Mult. Scler. 1, 2-9 (1995).
135. Yao DL, Liu X, Hudson LD, Webster HD. Insulin-like growth factor-I given subcutaneously reduces clinical deficits, decreases lesion severity and upregulates synthesis of myelin proteins in experimental autoimmune encephalomyelitis. Life Sci. 58, 1301-1306 (1996).
136. Cannella B, Pitt D, Capello E, Raine CS. Insulin-like growth factor-1 fails to enhance CNS myelin repair during autoimmune demyelination. Am. J. Pathol. 157, 933-943 (2000).
137. The IFN-B Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 655-661 (1993).
138. Paty DW, Li DK. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results: a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFN-B Multiple Sclerosis Study Group. Neurology 43, 662-667 (1993).
139. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39, 285-294 (1996).
140. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352, 1498-1504 (1998).
141. Simon JH, Jacobs LD, Campion M et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann. Neurol. 43, 79-87 (1998).
142. Randomized controlled trial of interferon-β-1a in secondary progressive MS, clinical results. Neurology 56, 1496-1504 (2001).
143. Hughes RA. Interferon-β-1a for secondary progressive multiple sclerosis. J. Neurol. Sci. 206, 199-202 (2003).
144. Leary SM, Thompson AJ. Interferon-β-1a in primary progressive multiple sclerosis. J. Neurol. Sci. 206, 215-216 (2003).
145. Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis, a systematic review. Arch. Intern. Med. 162, 2161-2169 (2002).
146. Filippini G, Munari L, Incorvaia B et al. Interferons in relapsing remitting multiple sclerosis, a systematic review. Lancet 361, 545-552 (2003).
147. Parry A, Corkill R, Blamire AM et al. β-interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J. Neurol. 250, 171-178 (2003).
148. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis, results of a Phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995 45, 1268-1276.
149. Johnson KP, Brooks BR, Ford CC et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. The Copolymer 1 Multiple Sclerosis Study Group. Mult. Scler. 6, 255-266 (2000).
150. Wolinsky JS, Comi G, Filippi M, Ladkani D, Kadosh S, Shifroni G. Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology 59, 1284-1286 (2002).
151. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann. Neurol. 49, 290-297 (2001).
152. Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF, implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 125, 2381-2391 (2002).
153. Paolillo A, Coles AJ, Molyneux PD et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53, 751-757 (1999).
154. Moreau T, Thorpe J, Miller D et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344, 298-301 (1994).
155. Miller DH, Khan OA, Sheremata WA et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348, 15-23 (2003).
156. Achiron A, Rotstein Z, Noy S, Mashiach S, Dulitzky M, Achiron R. Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. J. Neurol. 243, 25-28 (1996).
157. Haas J. High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult. Scler. 6(Suppl. 2), S18-S33 (2000).